MacHelle Sanders
Known title: DirectorCIK: 0001718020
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
BCRX Trades at 11x Forward Earnings, Analysts See $20.73 Target. BCRX is currently trading at about 11 times its forward earnings, which is on the lower side for the biotech sector. Analysts have an average target of $20.73, with a range from $11 to $32, while the stock sits near the bottom of its 52‑week range. This valuation gap raises questions about whether the market is pricing in potential challenges for the company.
Transaction History
| FTRE | ▼ Sell | Open Market | 9,700 | $175K | 8/3/2026 | View on chart |
| BCRX | ▲ Buy | Grant | 15,294 | $0 | 6/11/2026 | View on chart |
| FTRE | ▲ Buy | Option Exercise | 38,817 | $0 | 6/10/2026 | View on chart |
| BCRX | ▼ Sell | Open Market | 9,600 | $69K | 11/13/2025 | View on chart |
| BCRX | ▲ Buy | Grant | 12,500 | $0 | 6/12/2025 | View on chart |
| FTRE | ▲ Buy | Option Exercise | 7,282 | $0 | 5/14/2025 | View on chart |
| BCRX | ▼ Sell | Open Market | 4,689 | $28K | 6/17/2024 | View on chart |
| BCRX | ▲ Buy | Grant | 6,820 | $0 | 6/12/2024 | View on chart |
| BCRX | ▼ Sell | Open Market | 4,000 | $32K | 6/15/2023 | View on chart |
| BCRX | ▲ Buy | Grant | 16,745 | $0 | 6/13/2023 | View on chart |
| BCRX | ▲ Buy | Grant | 12,866 | $0 | 6/7/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Barclays Upgrades Fortrea, Boosts Target to $23
Barclays has upgraded Fortrea Holdings to overweight and lifted its target price to $23. The upgrade follows a recent rise in the stock price and a mention of the company as an overrated pick in a Yahoo article. Analysts still see upside potential, with the average target of $21.04 and a 52‑week range that includes the new level. The stock’s high‑beta rating indicates it may continue to move sharply with market swings.
Barclays Upgrades Fortrea, Boosts Target to $23. Barclays has upgraded Fortrea Holdings to overweight and lifted its target price to $23. The upgrade follows a recent rise in the stock price and a mention of the company as an overrated pick in a Yahoo article. Analysts still see upside potential, with the average target of $21.04 and a 52‑week range that includes the new level. The stock’s high‑beta rating indicates it may continue to move sharply with market swings.